Clinical Trial Update: A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma [Phase 2]

View source ↗

Summary

Phase 2 study of ACR-368 in endometrial adenocarcinoma is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Endometrial Adenocarcinoma

Drugs mentioned

• ACR-368

Snippet

Sponsor: Acrivon Therapeutics | Conditions: Endometrial Adenocarcinoma | Phase 2 | Status: RECRUITING